Well, in the Annual Report, which was released in late August, it was expected that the FDA 510(k) would be filed by July/August this year and that hernia sales would commence by the end of this year.
At the AGM in mid-November (post-lockdown), the advice was that the film extrusion and stretching facility would be completed by March and that it was anticipated that the first Syntrel would be available for use by Christmas this year.
I’ll accept the Company’s latest “end of 2021” guidance until I see evidence to the contrary.
As for speed of uptake by surgeons, it will depend upon the superiority and pricing of the Syntrel product compared with alternative options. This time round, PNV has the advantage of established accounts (>165), an established network of reps. and an existing product (BTM) that has established an excellent reputation among surgeons. So, hopefully, adoption will be even swifter than that for BTM.
PNV - Banter and General Comments, page-3829
-
- There are more pages in this discussion • 8,180 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.45 |
Change
0.010(0.41%) |
Mkt cap ! $1.691B | |||
| Open | High | Low | Value | Volume |
| $2.45 | $2.51 | $2.43 | $5.243M | 2.122M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 35541 | $2.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.46 | 2681 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |